TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-{alpha}).

Sujata Patil,Robert A. Figlin,Thomas E. Hutson,D. Michaelson,S. Negrier,Sinil Kim,Xin Huang,Robert J. Motzer

TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-{alpha}).

2010

Sujata Patil
Robert A. Figlin
Thomas E. Hutson
D. Michaelson
S. Negrier
Sinil Kim
Xin Huang
Robert J. Motzer

4594 Background: Sunitinib has shown significant improvement in progression-free survival (PFS) compared with IFN-α (11 vs. 5 months; p<0.001) and longer overall survival (26.4 vs. 21.8 months; p=0...

Keywords:

Cancer research
Interferon alfa
Renal cell carcinoma
Pathology
Endocrinology
Sunitinib
Internal medicine
Medicine
ifn alpha
overall survival
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations